SPATA17

Across TCGA pan-cancer cohorts, SPATA17 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SPATA17’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SPATA17 RNA is repressed in tumor relative to normal tissue. In most cancer types SPATA17 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, BLCA, and KIRC are the cancer types where SPATA17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPATA17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.102	<.001	11	view →
BLCA	Female	III,IV	+1.267	<.001	10	view →
KIRC	Male	All	−0.497	<.001	9	view →
COAD	Male	All	+0.377	<.001	9	view →
BRCA	All	III,IV	+1.079	<.001	6	view →
LUSC	All	II,III,IV	−0.590	.010	6	view →
STAD	All	All	+0.438	<.001	6	view →
CHOL	Male	All	+1.781	<.001	5	view →
HNSC	Male	All	+0.278	.001	4	view →
LIHC	Male	All	+0.083	.005	4	view →
KICH	All	All	−0.789	.011	3	view →
READ	All	III,IV	+0.765	.015	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SPATA17–THCA

Open the THCA breakdown →